Active surveillance for clinical complete responders after chemoradiotherapy for oesophageal squamous cell carcinoma.

BACKGROUND Guidelines on the treatment of oesophageal squamous cell carcinoma (SCC) recommend neoadjuvant chemoradiotherapy plus surgery or definitive chemoradiotherapy. The aim of this study was to evaluate the outcome of patients with a cCR after chemoradiotherapy who underwent active surveillance. METHODS Patients with oesophageal SCC who were treated with chemoradiotherapy between January 2016 and June 2022 were identified from an institutional database. Survival and recurrence of patients with a cCR who underwent active surveillance were compared with those of patients who underwent planned surgery. Survival was calculated according to the Kaplan-Meier method and compared between groups using the log rank test. RESULTS The 37 patients who underwent active surveillance were older and tumours were more often located in the middle/upper-third of the oesophagus than in the surgery group of 57 patients. Median follow-up was 28.1 (i.q.r. 17.2-47.1) months for the active surveillance group and 20 (12.9-39.1) months for the surgery group. Overall survival was comparable between the two groups, with 3-year survival rates of 50 (95% c.i. 31 to 67) and 59 (40 to 73)% for the active surveillance and surgery groups respectively (P = 0.55). Three-year progression-free survival for patients who underwent active surveillance was better than in the surgery group: 70 (43 to 85) versus 58 (40 to 72)% (P = 0.02). Overall and progression-free survival was comparable between patients in the active surveillance group and 23 patients in the surgery group who had a pCR (ypT0 N0). The overall recurrence rate was comparable between the groups: 7 of 37 (19.4%) in active surveillance group versus 16 of 49 (32.6%) in surgery group (P = 0.26). Locoregional recurrence was noted more often in the active surveillance group and systemic recurrence in the surgery group. CONCLUSION Active surveillance is feasible and safe for patients with oesophageal SCC who have a cCR after chemoradiotherapy.

[1]  O. Breathnach,et al.  Patient choice of surgery or surveillance following a clinical complete response to neoadjuvant chemoradiotherapy for oesophageal carcinoma. , 2023, The British journal of surgery.

[2]  V. Gebski,et al.  Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial , 2022, Frontiers in Oncology.

[3]  T. Leong,et al.  Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Ferlay,et al.  The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020. , 2022, Gastroenterology.

[5]  Hester F. Lingsma,et al.  Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer , 2021, Trials.

[6]  M. Pavarana,et al.  Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer , 2020, Cancers.

[7]  Laura H. Tang,et al.  Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Louie,et al.  Comment on: "Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer". , 2020, Annals of Surgery.

[9]  K. Lam,et al.  Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study , 2020, BMC Cancer.

[10]  D. Nieboer,et al.  Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer , 2019, Annals of surgery.

[11]  J. Fütterer,et al.  Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Yi Wang,et al.  Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta‐analysis , 2018, Thoracic cancer.

[13]  E. Steyerberg,et al.  Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. , 2018, The Lancet. Oncology.

[14]  David R. Jones,et al.  Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma , 2018, The Journal of thoracic and cardiovascular surgery.

[15]  Y. Soon,et al.  Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. , 2017, The Cochrane database of systematic reviews.

[16]  K. Muro,et al.  Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A) , 2017, Japanese journal of clinical oncology.

[17]  E. Blackstone,et al.  8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. , 2017, Annals of cardiothoracic surgery.

[18]  Arnulf H Hölscher,et al.  International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). , 2015, Annals of surgery.

[19]  C. Mariette,et al.  Is There a Role for Surgery for Patients with a Complete Clinical Response after Chemoradiation for Esophageal Cancer? An Intention-to-Treat Case-Control Study , 2013, Annals of surgery.

[20]  A. Ruol,et al.  Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary? , 2013, Journal of Gastrointestinal Surgery.

[21]  J. Ajani,et al.  Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[23]  R. van Hillegersberg,et al.  How to Define a Positive Circumferential Resection Margin in T3 Adenocarcinoma of the Esophagus , 2011, The American journal of surgical pathology.

[24]  T. Conroy,et al.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Nils Lehmann,et al.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Cooper,et al.  Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Dindo.  The Clavien–Dindo Classification of Surgical Complications , 2014 .

[28]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.